ALAUNOS THERAPEUTICS INC

Insider buys at Alaunos Therapeutics signal confidence as the company acquires Velaris, promising new cardiopulmonary assets and upside for long‑term investors.

Insider buying spurs hope for Alaunos Therapeutics as key investors buy at steep discounts, hinting at a potential rebound if clinical milestones are met.